Theravance Biopharma (TBPH) Current Deferred Revenue (2013 - 2023)

Theravance Biopharma (TBPH) has 11 years of Current Deferred Revenue data on file, last reported at $24000.0 in Q3 2023.

• Current Deferred Revenue for Q3 2023 came in at $24000.0, changed 0.0% year-over-year; the trailing twelve-month figure through Sep 2023 was $24000.0 (changed 0.0% YoY), and the FY2022 annual result was $24000.0, down 75.51% from the prior year.
• Current Deferred Revenue held at $24000.0 in Q3 2023 per TBPH's latest filing, from $24000.0 in the prior quarter.
• Over five years, Current Deferred Revenue peaked at $43.3 million in Q2 2019 and troughed at $24000.0 in Q2 2022.
• A 5-year average of $12.9 million and a median of $5.7 million in 2021 frame the typical range for Current Deferred Revenue.
• The sharpest annual moves came in 2022 and 2023: Current Deferred Revenue sank 99.58% in 2022, then changed 0.0% in 2023.
• A 5-year view of Current Deferred Revenue shows it stood at $31.6 million in 2019, then sank by 63.51% to $11.5 million in 2020, then tumbled by 99.15% to $98000.0 in 2021, then sank by 75.51% to $24000.0 in 2022, then changed by 0.0% to $24000.0 in 2023.
• Business Quant data shows TBPH's Current Deferred Revenue at $24000.0 in Q3 2023, $24000.0 in Q2 2023, and $24000.0 in Q1 2023.